THE THERAPEUTIC ACTIVITY OF PENICILLINS F, G, K, AND X IN EXPERIMENTAL INFECTIONS WITH PNEUMOCOCCUS TYPE I AND STREPTOCOCCUS PYOGENES.
1. The relative bactericidal activities of penicillins F, G, K, and X against Type I pneumococcus in vitro were 60, 100, 180, and 135. The corresponding activities against Streptococcus pyogenes, strain C-203, were 75, 100, 115, and 145, respectively. 2. The total curative doses (CD(50)) of penicillins F, G, K, and X in pneumococcal infections of white mice (ten injections at 3 hour intervals) were 4.6, 3.8, 20, and 2.4 mg. per kg., respectively, or relative activities of 83, 100, 19, and 160, referred to G as 100. 3. The corresponding curative doses in streptococcal infections of white mice were 2.6, 1.3, 14.0, and 0.5 mg. per kg., or relative activities of 50, 100, 9, and 260. 4. Penicillin K was therefore one-tenth as active in vivo as would be implied by its bactericidal activity in vitro. This probably reflects its rapid inactivation in vivo, evidenced by the low and evanescent blood levels observed in both rabbits and man, and the low urinary recovery of this species of penicillin. 5. Penicillin X was significantly more active therapeutically than its bactericidal activity in vitro would imply. This probably reflects its slower inactivation in vivo, evidenced by the somewhat higher and more prolonged blood levels afforded by this penicillin in comparison with penicillin G. Judged by the mouse infections with the strains here used, penicillin X is the penicillin of choice in the treatment of infections with pneumococcus Type I and hemolytic streptococci. 6. The curative dose of penicillin in streptococcal and pneumococcal infections paralleled the varying susceptibility of these organisms to penicillin in vitro.
Eagle
H
H
Laboratory of Experimental Therapeutics of the United States Public Health Service and The Johns Hopkins School of Hygiene, Baltimore.
D000818:Animals; D006801:Humans; D007239:Infections; D008297:Male; D051379:Mice; D010400:Penicillin G / Q000031:analogs & derivatives; D010406:Penicillins / Q000494:pharmacology* / Q000628:therapy*; D011008:Pneumococcal Infections; D011817:Rabbits; D013290:Streptococcal Infections; D013291:Streptococcus; D013296:Streptococcus pneumoniae; D013297:Streptococcus pyogenes
D010406:Penicillins; C065221:penicillin K; C067075:penicillin F; D010400:Penicillin G; C037825:penicillin X